Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for the treatment of mild to moderate dementia associated with Alzheimer's disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Luye Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 05, 2024
Details:
Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.
Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area: Neurology Product Name: P2B001
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Pharma Two B
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 18, 2021